First-in-man study of E-3810, a novel VEGFR and FGFR inhibitor, in patients with advanced solid tumors.

被引：2
|
作者：
Soria, J.
De Braud, F. G.
Cereda, R.
Bahleda, R.
Delmonte, A.
Angevin, E.
Varga, A.
Noberasco, C.
Dall'O, E.
Lassau, N.
Dromain, C.
Bellomi, M.
Farace, F.
Bertolini, F.
Zucchetti, M.
Marsoni, S.
Camboni, M. G.
机构：
[1] Inst Gustave Roussy, Villejuif, France
[2] European Inst Oncol, Milan, Italy
[3] EOS SpA, Milan, Italy
[4] SENDO, Milan, Italy
[5] Mario Negri Inst Pharmacol Res, Milan, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.tps149
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS149
引用
收藏
页数：1
相关论文
共 50 条
  • [41] First-in-human phase 1 study of E7090, a novel selective inhibitor of FGFRs, in patients with advanced solid tumors
    Koyama, Takafumi
    Shimizu, Toshio
    Iwasa, Satoru
    Fujiwara, Yutaka
    Kondo, Shunsuke
    Kitano, Shigehisa
    Yonemori, Kan
    Shimomura, Akihiko
    Iizumi, Sakura
    Sasaki, Tatsuya
    Furuse, Junji
    Yamamoto, Noboru
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
  • [42] First-in-human study of oral S 49076, a MET/AXL/FGFR inhibitor, in advanced solid tumors
    Postel-Vinay, S.
    Hollebecque, A.
    Soria, J. -C.
    Balandraud, S.
    Brendel, K.
    Cattan, V.
    Jacquet-Bescond, A.
    Busto, N. Lopez
    Malasse, S.
    Marfai, L.
    Pauly, J.
    Prudkin, L.
    Azaro, A.
    Rodon, J.
    ANNALS OF ONCOLOGY, 2015, 26 : 37 - 37
  • [43] Exploratory biomarker analysis of a phase I study of AZD4547, an inhibitor of fibroblast growth factor receptor (FGFR), in patients with advanced solid tumors.
    Kilgour, Elaine
    Ferry, David
    Saggese, Matilde
    Arkenau, Hendrik-Tobias
    Rooney, Claire
    Smith, Neil R.
    Baker, Dawn
    Dougherty, Brian
    Womack, Chris
    Smith, Paul D.
    Ghiorghiu, Dana C.
    Harrington, Elizabeth A.
    Barrett, J. Carl
    Brooks, Nigel
    Stockman, Paul
    Andre, Fabrice
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [44] A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors.
    Sehdev, Amikar
    Zha, Yuanyuan
    Karrison, Theodore G.
    Janisch, Linda A.
    Cohen, Ezra E. W.
    Maitland, Michael L.
    Polite, Blase N.
    Turcich, Michelle
    Fleming, Gini F.
    Salgia, Ravi
    Pinto, Navin R.
    Gajewski, Thomas
    Bissonnette, Marc
    Ratain, Mark J.
    Sharma, Manish
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [45] A phase I study of the VEGFR kinase inhibitor vatalanib in combination with the mTOR inhibitor, everolimus, in patients with advanced solid tumors
    Zhu, Mojun
    Molina, Julian R.
    Dy, Grace K.
    Croghan, Gary A.
    Qi, Yingwei
    Glockner, James
    Hanson, Lorelei J.
    Roos, Michelle M.
    Tan, Angelina D.
    Adjei, Alex A.
    INVESTIGATIONAL NEW DRUGS, 2020, 38 (06) : 1755 - 1762
  • [46] A phase I study of the VEGFR kinase inhibitor vatalanib in combination with the mTOR inhibitor, everolimus, in patients with advanced solid tumors
    Mojun Zhu
    Julian R. Molina
    Grace K. Dy
    Gary A. Croghan
    Yingwei Qi
    James Glockner
    Lorelei J. Hanson
    Michelle M. Roos
    Angelina D. Tan
    Alex A. Adjei
    Investigational New Drugs, 2020, 38 : 1755 - 1762
  • [47] First-in-human trial of novel oral PARP inhibitor BMN 673 in patients with solid tumors.
    De Bono, Johann Sebastian
    Mina, Lida A.
    Gonzalez, Michael
    Curtin, Nicola J.
    Wang, Evelyn
    Henshaw, Joshua W.
    Chadha, Manpreet
    Sachdev, Jasgit C.
    Matei, Daniela
    Jameson, Gayle S.
    Ong, Michael
    Basu, Bristi
    Wainberg, Zev A.
    Byers, Lauren Averett
    Chugh, Rashmi
    Dorr, Andrew
    Kaye, Stanley B.
    Ramanathan, Ramesh K.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [48] First-in-human study of TU2218, TGFbRI and VEGFR2 dual inhibitor in patients with advanced solid tumors
    Oh, D. Y.
    Lee, E.
    Tolcher, A. W.
    Kim, K. P.
    Kim, H. T.
    ANNALS OF ONCOLOGY, 2023, 34 : S633 - S633
  • [49] MGCD265, a multitargeted oral tyrosine kinase receptor inhibitor of Met and VEGFR, in combination with erlotinib in patients with advanced solid tumors.
    O'Dwyer, Peter J.
    Papadopoulos, Kyriakos P.
    Tolcher, Anthony W.
    Teitelbaum, Ursina R.
    Harlacker, Kathleen
    Smith, Lon S.
    Sohal, Davendra
    Rasco, Drew Warren
    Beeram, Muralidhar
    Mehran, Mariam
    Tawashi, Manal
    Drouin, Michel A.
    Wang, James
    Fournel, Marielle
    Maroun, Christiane R.
    Karam, Andre
    Besterman, Jeffrey M.
    Patnaik, Amita
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [50] A phase I study of IPI-926, a novel hedgehog pathway inhibitor, in patients (pts) with advanced or metastatic solid tumors.
    Rudin, C. M.
    Jimeno, A.
    Miller, W. H.
    Eigl, B. J.
    Gettinger, S. N.
    Chang, A. L. S.
    Faia, K.
    Sweeney, J.
    Loewen, G.
    Ross, R. W.
    Weiss, G. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345